BioMerieux has purchased 100% of PML Microbiologicals’s shares from the privately held Pelican Life Sciences Group, based in San Diego, California (US) for $29.6 million.
The acquisition will enable BioMerieux to become a leading provider in the US of microbiology testing solutions for pharmaceutical companies. In addition, BioMerieux will enter the North American clinical prepared culture media (PPM) market, becoming the number one PPM provider for clinical applications in Canada.
PML’s sites in Portland and Toronto will join BioMerieux’s worldwide network of culture media production centers with its main site in Craponne (France) and regional facilities in Lombard, Illinois (US), Madrid (Spain), Basingstoke (England), Brisbane (Australia) and Rio de Janeiro (Brazil).
Stephane Bancel, CEO of BioMerieux, said: “This new acquisition, our sixth in two years, reinforces the North American market position of BioMerieux’s core business, microbiology. In the current challenging economic context, we are pleased to add another reagent-only business to our portfolio that will boost BioMerieux’s recurring sales.”